Table of Contents
Jefferies Global Healthcare Conference in London
Date: November 17-20, 2025
To view the webcast, please click here.
Jefferies Global Healthcare Conference in London
Related
FDA Grants Orphan Drug Designation to Affinia Therapeutics' AFTX-201 for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)
The FDA has granted Orphan Drug designation to Affinia Therapeutics' AFTX-201, a one-time IV gene therapy for BAG3-associated dilated cardiomyopathy. It follows a recent Fast Track grant; AFTX-201 is in the Phase 1/2 UPBEAT trial recruiting across the U.S. and Canada.
Affinia Therapeutics to Present AFTX-201 for BAG3-Associated Dilated Cardiomyopathy (DCM) and Highlight Proprietary Capsid Engineering and Manufacturing Data at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Affinia Therapeutics will present new AFTX-201 preclinical data, the UPBEAT Phase 1/2 trial design, and proprietary capsid engineering and manufacturing advancements across two oral and four poster sessions at ASGCT 2026 in Boston, May 11-15.
DemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)
DemeRx announced that the FDA has accepted its IND application for DMX-1001 (oral noribogaine), a novel neuroplastogen therapeutic for the treatment of alcohol use disorder (AUD).
Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)
Affinia Therapeutics announced Health Canada’s approval of its clinical trial application for AFTX-201, a potential best-in-class investigational genetic medicine for the treatment of BAG3-associated dilated cardiomyopathy (DCM).
Comments